F2G
Manchester
About F2G
F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversified into chemistry-driven discovery. They have also assembled an experienced development capacity.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $383.3M
- Funding stage: Late Stage Venture
- Last round: Series H (Sep 2024)
- Website: f2g.com
- Phone: 44 (0)161 785 1270
Industries & Categories
Biotechnology, Genetics, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/f2g-73296 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.